Johnson & Johnson, the world’s biggest health-products maker, recalled about 4 million packages of Children’s Benadryl allergy tablets and about 800,000 bottles of junior-strength Motrin caplets, citing manufacturing lapses.
“When the manufacturing process was developed, it was not done as thoroughly as it should have been,” Bonnie Jacobs, a J&J spokeswoman, said in a telephone interview today. “There is no indication that the product does not meet quality standards.”
J&J’s McNeil unit withdrew more than 40 types of children’s over-the-counter liquid medicines in April, forcing a suspension of production at a manufacturing plant and reducing 2010 sales about $600 million, the New Brunswick, New Jersey-based company said in July. The U.S. House Oversight and Government Reform Committee has been investigating J&J’s handling of the recall and a separate incident involving Motrin tablets.
While the McNeil unit of J&J posted a notice Nov. 15 about the recall on the Benadryl website, it didn’t issue a press statement, Jacobs said. The action “is not being taken on the basis of adverse events,” or safety issues, Jacobs said.
More...
A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to intervene in Bayer’s...
As marijuana use among teens has grown in the past decade, researchers have been trying to...
The Food and Drug Administration Monday unveiled the details of a new policy designed to make...
